-
公开(公告)号：EP3332006A1
公开(公告)日：2018-06-13
申请号：EP16832346.7
申请日：2016-08-05
发明人： ZHENG, Yong , LI, Jing , CHEN, Zhisheng
IPC分类号： C12N15/09 , C12P21/08 , C07K16/28 , C12N5/00 , A61K39/395
CPC分类号： C07K16/2827 , C07K2317/21 , C07K2317/33 , C07K2317/70 , C07K2317/76 , C07K2317/92
摘要： The present disclosure provides monoclonal antibodies against protein programmed cell death 1 ligand (PD-L1), which can block the binding of PD-L1 to PD-1, and therefore block the inhibitory function of PD-L1 on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.
-
2.发明公开
公开(公告)号：EP3773720A1
公开(公告)日：2021-02-17
申请号：EP19785334.4
申请日：2019-04-10
申请人： Wuxi Biologics (Shanghai) Co. Ltd. , Wuxi Biologics Ireland Limited. , Open Monoclonal Technology, Inc.
发明人： ZHENG, Yong , LIU, Jingjing , LI, Jing
-
公开(公告)号：EP3790903A1
公开(公告)日：2021-03-17
申请号：EP19799456.9
申请日：2019-05-07
发明人： ZHENG, Yong , YANG, Baotian , LI, Jing
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00 , A61P37/00 , A61P31/00
-
公开(公告)号：EP4074732A1
公开(公告)日：2022-10-19
申请号：EP22174660.5
申请日：2019-05-07
发明人： ZHENG, Yong , YANG, Baotian , LI, Jing
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00 , A61P37/00 , A61P31/00
摘要： The present application provides fully human monoclonal antibodies against tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), also known as OX40 and CD134. It also provides the methods of hybridoma generation using a humanized transgenic rat, the nucleic acid molecules encoding the anti-OX40 antibodies, expression vectors and host cells used for the expression of anti-OX40 antibodies. The invention further provides the methods for validating the function of antibodies in vitro and the efficacy of antibodies in vivo. The antibodies of invention provide a very potent agent for the treatment of multiple cancers vial modulating human immune function.
-
公开(公告)号：EP4200334A1
公开(公告)日：2023-06-28
申请号：EP21857750.0
申请日：2021-08-20
发明人： YANG, Baotian , LI, Jin , ZHENG, Yong
IPC分类号： C07K16/28 , C12N15/13 , A61K39/395 , A61P35/00 , A61P37/02
-
公开(公告)号：EP3307777A1
公开(公告)日：2018-04-18
申请号：EP15894637.6
申请日：2015-06-11
发明人： ZHENG, Yong , LI, Jing , CHEN, Zhisheng
CPC分类号： C07K16/2827 , C07K2317/24 , C07K2317/565 , C07K2317/74 , C07K2317/76 , C07K2317/92 , G01N33/566 , G01N2333/70596 , G01N2800/52
摘要： The present disclosure provides monoclonal antibodies against protein programmed cell death 1 ligand (PD-L1), which can block the binding of PD-L1 to PD-1, and therefore block the inhibitory function of PD-L1 on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.
-
公开(公告)号：EP3334763A1
公开(公告)日：2018-06-20
申请号：EP16834675.7
申请日：2016-08-11
发明人： ZHENG, Yong , LI, Jing , CHEN, Zhisheng
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2818 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/74 , C07K2317/76 , C07K2317/92
摘要： The present disclosure provides monoclonal antibodies against protein programmed cell death 1 (PD-1), which can block the binding of PD-1 ligands to PD-1, and therefore block the inhibitory function of PD-1 ligands on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.015 秒)
